% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Albrecht:302158,
      author       = {P. Albrecht$^*$ and E. Karabati$^*$ and M. P. Ebert and J.
                      Betge$^*$},
      title        = {{G}astric cancer: from biomarkers to functional precision
                      medicine.},
      journal      = {Trends in molecular medicine},
      volume       = {nn},
      issn         = {1471-4914},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-01276},
      pages        = {nn},
      year         = {2025},
      note         = {#EA:B440#LA:B440# / epub},
      abstract     = {Gastric cancer (GC) remains a deadly disease because of
                      late detection and limited treatment options at advanced
                      stages. Treatment of patients with metastatic disease is
                      based on chemotherapy, complemented by antibodies targeting
                      HER2, VEGFR2, and more recently PD-1 or claudin 18.2.
                      Further targets, such as FGFR2b, as well as novel drug
                      classes including antibody-drug conjugates (ADCs) and
                      bispecific antibodies, are promising developments in GC
                      treatment. Despite the failure of several targeted agents,
                      the landscape of GC therapy is evolving rapidly, facilitated
                      by umbrella or platform precision medicine trials. The
                      integration of next-generation sequencing and other omics
                      techniques into molecular tumor boards, as well as
                      functional drug testing on patient-derived models, might
                      bring us closer to personalized oncology and ultimately
                      improve patient survival.},
      subtyp        = {Review Article},
      keywords     = {functional precision medicine (Other) / gastroesophageal
                      adenocarcinoma (Other) / immunotherapy (Other) /
                      patient-derived organoids (Other) / precision oncology
                      (Other) / targeted therapy (Other)},
      cin          = {B440 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B440-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40555635},
      doi          = {10.1016/j.molmed.2025.05.007},
      url          = {https://inrepo02.dkfz.de/record/302158},
}